{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:33:11Z","timestamp":1777545191487,"version":"3.51.4"},"reference-count":53,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Bartonella henselae can cause various infections in humans, ranging from benign and self-limiting diseases to severe and life-threatening diseases as well as persistent infections that are difficult to treat. To develop more effective treatments for persistent Bartonella infections, in this study, we performed a high-throughput screen of an FDA-approved drug library against stationary phase B. henselae using the SYBR Green I\/propidium iodide (PI) viability assay. We identified 110 drug candidates that had better activity against stationary phase B. henselae than ciprofloxacin, and among the top 52 drug candidates tested, 41 drugs were confirmed by microscopy to have higher activity than the current frontline antibiotic erythromycin. The identified top drug candidates include pyrvinium pamoate, daptomycin, methylene blue, azole drugs (clotrimazole, miconazole, sulconazole, econazole, oxiconazole, butoconazole, bifonazole), aminoglycosides (gentamicin and streptomycin, amikacin, kanamycin), amifostine (Ethyol), antiviral Lopinavir\/ritonavir, colistin, nitroxoline, nitrofurantoin, verteporfin, pentamidine, berberine, aprepitant, olsalazine, clinafloxacin, and clofoctol. Pyrvinium pamoate, daptomycin, methylene blue, clotrimazole, and gentamicin and streptomycin at their respective maximum drug concentration in serum (Cmax) had the capacity to completely eradicate stationary phase B. henselae after 3-day drug exposure in subculture studies. While the currently used drugs for treating bartonellosis, including rifampin, erythromycin, azithromycin, doxycycline, and ciprofloxacin, had very low minimal inhibitory concentration (MIC) against growing B. henselae, they had relatively poor activity against stationary phase B. henselae, except aminoglycosides. The identified FDA-approved agents with activity against stationary phase B. henselae should facilitate development of more effective treatments for persistent Bartonella infections.<\/jats:p>","DOI":"10.3390\/antibiotics8020050","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T07:01:22Z","timestamp":1556521282000},"page":"50","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Identification of FDA-Approved Drugs with Activity against Stationary Phase Bartonella henselae"],"prefix":"10.3390","volume":"8","author":[{"given":"Tingting","family":"Li","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA"},{"name":"Department of Immunology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA"},{"name":"Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzhen","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA"},{"name":"Department of Clinical Microbiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanliang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5908-307X","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1128\/CMR.00013-17","article-title":"Bartonella species, an emerging cause of blood-culture-negative endocarditis","volume":"30","author":"Okaro","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/9781119278368.ch5.2","article-title":"Bartonellosis, One Health and all creatures great and small","volume":"28","author":"Breitschwerdt","year":"2017","journal-title":"Vet. Dermatol."},{"key":"ref_3","first-page":"8","article-title":"Natural history of Bartonella infections (an exception to Koch\u2019s postulate)","volume":"9","author":"Jacomo","year":"2002","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/JCM.39.8.2978-2980.2001","article-title":"Immunofluorescent Detection of IntraerythrocyticBartonella henselae in Naturally Infected Cats","volume":"39","author":"Rolain","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mosepele, M., Mazo, D., and Cohn, J. (2012). Bartonella infection in immunocompromised hosts: Immunology of vascular infection and vasoproliferation. Clin. Dev. Immunol.","DOI":"10.1155\/2012\/612809"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/archneur.58.9.1357","article-title":"Concurrent infection of the central nervous system by Borrelia burgdorferi and Bartonella henselae: Evidence for a novel tick-borne disease complex","volume":"58","author":"Eskow","year":"2001","journal-title":"Arch. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3201\/eid1203.050931","article-title":"Bartonella spp. in pets and effect on human health","volume":"12","author":"Chomel","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijantimicag.2014.04.006","article-title":"Pathogenicity and treatment of Bartonella infections","volume":"44","author":"Angelakis","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2217\/fmb.10.133","article-title":"Bartonella infection: Treatment and drug resistance","volume":"5","author":"Biswas","year":"2010","journal-title":"Future Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00006454-199702000-00002","article-title":"The expanding spectrum of Bartonella infections: II. Cat-scratch disease","volume":"16","author":"Bass","year":"1997","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1038\/emi.2014.3","article-title":"Persisters, Persistent Infections and the Yin-Yang Model","volume":"3","author":"Zhang","year":"2014","journal-title":"Emerg. Microb. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Feng, J., Wang, T., Zhang, S., Shi, W., and Zhang, Y. (2014). An optimized SYBR Green I\/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferi. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111809"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1038\/emi.2014.53","article-title":"Identification of Novel Activity against Borrelia burgdorferi Persisters Using an FDA Approved Drug Library","volume":"3","author":"Feng","year":"2014","journal-title":"Emerg. Microb. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/antibiotics4030397","article-title":"Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library","volume":"4","author":"Feng","year":"2015","journal-title":"Antibiotics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fmicb.2016.00743","article-title":"A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library","volume":"7","author":"Feng","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1128\/JCM.02403-10","article-title":"Combining culture techniques for Bartonella: The best of both worlds","volume":"49","author":"Lynch","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AEM.00621-08","article-title":"Analysis of a Novel Insect Cell Culture Medium-Based Growth Medium for Bartonella Species","volume":"74","author":"Riess","year":"2008","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_18","unstructured":"(2018, December 13). Performance Standards for Antimicrobial Susceptibility Testing. Available online: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1128\/AAC.48.6.1921-1933.2004","article-title":"Recommendations for treatment of human infections caused by Bartonella species","volume":"48","author":"Rolain","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/AAC.02011-12","article-title":"Blood, tissue and intracellular concentrations of Azithromycin during and after end of therapy","volume":"57","author":"Matzneller","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cpt1976196802","article-title":"Absorption of pyrvinium pamoate","volume":"19","author":"Smith","year":"1976","journal-title":"Clin. Pharmacol. Therap."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-008-0563-x","article-title":"High absolute bioavailability of methylene blue given as an aqueous oral formulation","volume":"65","author":"Rengelshausen","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1128\/AAC.11.3.462","article-title":"Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects","volume":"11","author":"Welling","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s002280050350","article-title":"Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva","volume":"53","author":"Goetschi","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1128\/AAC.45.9.2529-2535.2001","article-title":"Pharmacokinetics of clinafloxacin after single and multiple doses","volume":"45","author":"Randinitis","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/1120009X.2017.1380357","article-title":"Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections","volume":"29","author":"Novelli","year":"2017","journal-title":"J. Chemother."},{"key":"ref_28","first-page":"873","article-title":"Present status of nitroxoline","volume":"35","author":"Berthelot","year":"1987","journal-title":"Pathol. Biol. (Paris)"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1164\/ajrccm\/140.6.1607","article-title":"Comparison of plasma concentrations of aerosolized pentamidine in nonventilated and ventilated patients with pneumocystosis","volume":"140","author":"Girard","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/pgmj.55.647.662","article-title":"Pharmacokinetics of imidazole antimycotics","volume":"55","author":"Plempel","year":"1979","journal-title":"Postgrad Med. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/AAC.41.5.1115","article-title":"Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing","volume":"41","author":"Demczar","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jpba.2007.03.022","article-title":"Determination of berberine in human plasma by liquid chromatography\u2013electrospray ionization\u2013mass spectrometry","volume":"44","author":"Hua","year":"2007","journal-title":"J. Pharma Biomed. Anal."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.ajkd.2003.08.027","article-title":"Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin","volume":"42","author":"Kays","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4236\/pp.2012.32026","article-title":"Pharmacokinetic Disposition of Streptomycin Sulfate in Japanese Eel (Anguilla japonica) after Oral and Intramuscular Administrations","volume":"3","author":"He","year":"2012","journal-title":"Pharmacol. Pharma."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0924-8579(97)00050-2","article-title":"Pharmacokinetics of miconazole in serum and exudate of pelvic retroperitoneal space after radical hysterectomy and pelvic lymphadenectomy","volume":"9","author":"Mikamo","year":"1998","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.1128\/AAC.01032-15","article-title":"Optimizing the initial amikacin dosage in adults","volume":"59","author":"White","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00280-010-1519-2","article-title":"Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients","volume":"68","author":"Takahashi","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","first-page":"39","article-title":"A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay","volume":"14","author":"Danesi","year":"1988","journal-title":"Drugs Exp. Clin. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/AAC.01741-13","article-title":"Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis","volume":"58","author":"Koomanachai","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","first-page":"703","article-title":"Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors","volume":"9","author":"Souid","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jac\/dkl341","article-title":"In vitro susceptibility of Bartonella species to 17 antimicrobial compounds: Comparison of Etest and agar dilution","volume":"58","author":"Sander","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/CMR.13.3.428","article-title":"Bartonella infection in animals: Carriership, reservoir potential, pathogenicity, and zoonotic potential for human infection","volume":"13","author":"Breitschwerdt","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.47.2.614-619.2003","article-title":"Culture and antibiotic susceptibility of Bartonella quintana in human erythrocytes","volume":"47","author":"Rolain","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.neurobiolaging.2010.12.012","article-title":"Lest we forget you\u2014methylene blue","volume":"32","author":"Schirmer","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/1874285801610010012","article-title":"Antifungal Action of Methylene Blue Involves Mitochondrial Dysfunction and Disruption of Redox and Membrane Homeostasis in C. albicans","volume":"10","author":"Ansari","year":"2016","journal-title":"Open Microbiol. J."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Feng, J., Auwaerter, P.G., and Zhang, Y. (2015). Drug Combinations against Borrelia burgdorferi Persisters In Vitro: Eradication Achieved by Using Daptomycin, Cefoperazone and Doxycycline. PLoS ONE.","DOI":"10.1371\/journal.pone.0117207"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.47.8.2538-2544.2003","article-title":"Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus","volume":"47","author":"Silverman","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1128\/AAC.02005-12","article-title":"The target of daptomycin is absent from Escherichia coli and other gram-negative pathogens","volume":"57","author":"Randall","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","first-page":"722","article-title":"Clotrimazole as a cancer drug: A short review","volume":"4","author":"Kadavakollu","year":"2014","journal-title":"Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1248\/bpb.27.361","article-title":"Enhancement of heme-induced membrane damage by the anti-malarial clotrimazole: The role of colloid-osmotic forces","volume":"27","author":"Huy","year":"2004","journal-title":"Biol. Pharmacol. Bull."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: Mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1574-6976.2012.00324.x","article-title":"Persistence of Bartonella spp. stealth pathogens: From subclinical infections to vasoproliferative tumor formation","volume":"36","author":"Pulliainen","year":"2012","journal-title":"FEMS Microbiol. Rev."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/2\/50\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:47:58Z","timestamp":1760186878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/2\/50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["antibiotics8020050"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics8020050","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]}}}